BioSpace News Archive

MannKind Corporation will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced that its Board of Directors has accepted the resignation of Francis deSouza as Illumina’s Chief Executive Officer and as a Director, effective Sunday, June 11.

Kura Oncology, Inc. announced updated clinical data from KOMET-001, a Phase 1/2 clinical trial of the Company’s potent and selective menin inhibitor, ziftomenib, including significant clinical activity in patients with heavily pretreated and co-mutated relapsed/refractory NPM1-mutant acute myeloid leukemia.

Data of InnoCare’s robust pipelines were presented at the European Hematology Association 2023 Hybrid Congress.

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, announced updated interim results from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002.

Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, announced a CNY 180 million Series B financing.

On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of “Sanyou Super Trillion Common Light Chain Antibody Discovery Platform”.

Innovent Biologics, Inc. announced that Phase 1 clinical data of the globally first anti-CD47/PD-L1 bispecific antibody IBI322 for the treatment of anti-PD-1-resistant patients with classic Hodgkin lymphoma was presented in oral presentation at the 28th Annual Meeting of the European Society of Hematology.